Oculis is acquiring Privosegtor and ACT-02 assets from Accure for $3.8 million upfront cash and up to 2,050,000 ordinary shares. This transaction enhances Oculis's strategic flexibility and ownership of a neuroprotective drug candidate currently in registrational trials, potentially driving long-term value.
Oculis is acquiring Privosegtor and ACT-02 assets from Accure, a move that significantly enhances its strategic position by gaining full ownership of a neuroprotective drug candidate, Privosegtor. This drug is already in registrational trials for optic neuropathies and acute MS relapses, with an IND submission planned for Q4 2026, indicating a relatively advanced stage of development. The deal structure, involving an upfront cash payment and performance-based share issuance, aligns Accure's interests with Oculis's success. This acquisition could be a long-term value driver for Oculis, as successful development and commercialization of Privosegtor would open up new market opportunities. For traders, this presents a long-term opportunity for OCUL if the drug progresses successfully through trials, but also carries the inherent risks of drug development.